Jaguar Health Highlights Pet Cancer Awareness with Its Cancer Care Initiatives

Jaguar Health, Inc. celebrates National Pet Cancer Awareness Month, focusing on pet cancer, particularly in dogs and cats. The company's Canalevia®-CA1, a prescription drug conditionally approved by the FDA, is designed to treat chemotherapy-induced diarrhea (CID) in dogs. This makes it the first FDA-approved treatment for CID in dogs.

Lisa Conte, Jaguar's CEO, notes the widespread occurrence of cancer in dogs, affecting up to 50% of dogs over ten years old. Jaguar emphasizes its commitment to supportive cancer care through its "Make Cancer Less Shitty" program, which aims to increase awareness and enhance supportive care for cancer patients.

Canalevia-CA1, available by prescription, is a formulation of crofelemer, a plant-based product. Jaguar's focus on cancer care reflects the broader initiative to address supportive care gaps and advocate for pet health.